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Abstract Introduction
Glycation, oxidation, and browning of proteins have all been
implicated in the development of diabetic complications. We
measured the initial Amadori adduct, fructoselysine (FL); two
Maillard products, NE-(carboxymethyl) lysine (CML) and
pentosidine; and fluorescence (excitation = 328 nm, emission
= 378 nm) in skin collagen from 39 type 1 diabetic patients
(aged 41.5±15.3 117-731 yr; duration of diabetes 17.9±11.5
10-461 yr, Imean±SD, rangel). The measurements were re-
lated to the presence of background (n = 9) or proliferative (n
= 16) retinopathy; early nephropathy (24-h albumin excretion
rate IAER241 > 20 Ag/min; n = 9); and limited joint mobility
(LJM; n = 20). FL, CML, pentosidine, and fluorescence in-
creased progressively across diabetic retinopathy (P < 0.05, P
< 0.001, P < 0.05, P < 0.01, respectively). FL, CML, pentosi-
dine, and fluorescence were also elevated in patients with early
nephropathy (P < 0.05, P < 0.001, P < 0.01, P < 0.01, respec-
tively). There was no association with LJM. Controlling for
age, sex, and duration of diabetes using logistic regression, FL
and CML were independently associated with retinopathy (FL
odds ratio (OR) = 1.06, 95% confidence interval (CI) = 1.01-
1.12, P < 0.05; CML OR = 6.77, 95% CI = 1.33-34.56, P
< 0.05) and with early nephropathy (FL OR = 1.05, 95% CI
= 1.01-1.10, P < 0.05; CML OR = 13.44, 95% CI = 2.00-
93.30, P < 0.01). The associations between fluorescence and
retinopathy and between pentosidine and nephropathy ap-
proached significance (P = 0.05). These data show that FL and
Maillard products in skin correlate with functional abnormali-
ties in other tissues and suggest that protein glycation and oxi-
dation (glycoxidation) may be implicated in the development of
diabetic retinopathy and early nephropathy. (J. Clin. Invest.
1993. 91:2470-2478.) Key words: collagen * complications of
diabetes * glycation * oxidation - nonenzymatic browning
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A central issue in current diabetes research concerns the patho-
genesis of diabetic complications (1-7), and in particular, the
role of hyperglycemia in their development (8). Despite the
problems involved in obtaining a satisfactory index of long-
term blood glucose control, many clinical and epidemiological
studies have supported an association between glycemic con-
trol and complications (9-17). Glycation (nonenzymatic gly-
cosylation), a ubiquitous chemical modification of proteins
exposed to reducing sugars, provides the basis for an attractive
hypothesis to explain this association. This hypothesis states
that the biochemical, structural and functional consequences
ofincreased protein glycation contribute to the development of
complications.
Collagen is a long-lived protein found throughout the body.
With advancing age, it undergoes marked physicochemical
changes, including decreased solubility, elasticity, and sensitiv-
ity to protease digestion (18), and increased thermal stability
(19, 20). These changes are accelerated in diabetic patients
(21), whose collagen contains significantly increased quanti-
ties of the initial product of glycation, fructoselysine (FL)'
(22). However, there is little evidence to date that FL is directly
implicated in the altered properties ofcollagen. The FL content
of skin collagen increases only slightly with age in nondiabetic
individuals (22, 23), and although elevated in diabetes, it is
unrelated to age or duration of diabetes (22). In existing stud-
ies, collagen FL has not been associated with the presence or
severity of diabetic complications (24, 25), and even in pa-
tients with long-standing diabetes, its concentration in collagen
falls promptly with improved glycemic control (26). In vitro,
short-term glycation ofcollagen does not increase its resistance
to enzymatic digestion (27).
FL may, however, be indirectly linked with the altered prop-
erties of collagen in both aging and diabetes. In long-lived pro-
teins, FL undergoes further dehydration, rearrangement, and
cleavage reactions, which comprise the later stages ofthe Mail-
lard reaction (28-30). Many of these reactions involve oxida-
tive processes, and their products, whose formation (in con-
trast to that of FL) is irreversible (26), have recently been
termed "glycoxidation products" (6). Oxidation may there-
fore be regarded as a "fixative" ofglycative damage to proteins.
The intimate interrelationship between glycation and oxida-
1. Abbreviations used in this paper: AER24, 24-h albumin excretion
rate; CI, confidence interval; CML, N-(carboxymethyl)lysine; FL,
fructoselysine, Hb, hemoglobin; LJM, limitation of joint mobility;
MHbA,, mean HbA,, OR, odd ratio.
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tion is further emphasized by the observation that increased
glycation may, in itself, promote the formation of free radicals
and therefore enhance oxidative damage to proteins and lipids
(31). In collagen, glycoxidation products are insoluble, fre-
quently pigmented or fluorescent, and include glucose-derived
cross-links (6). They accumulate with advancing age (22, 23,
32), and at an accelerated rate in diabetes (22, 32-36), parallel-
ing the physicochemical alterations described above. In vitro,
glycoxidation of collagen causes the physicochemical alter-
ations characteristic ofaging (34, 37). Thus, the accumulation
of late Maillard or glycoxidation products may contribute sig-
nificantly to the altered physical properties of collagen in both
aging and diabetes (21, 33, 34, 36), and to the development of
diabetic complications (32, 38-44).
In this and the accompanying study (22), FL, two glycoxi-
dation products, NE-(carboxymethyl) lysine (CML) (23, 45-
47) and pentosidine (32, 48-51), and Maillard-type fluores-
cence have been measured in skin collagen from type 1 diabetic
patients. The accumulation ofCML, pentosidine, and fluores-
cence throughout life, and their accelerated accumulation in
diabetes, have been described in the preceding article (22).
Here we relate the levels of FL, CML, pentosidine, and colla-
gen-linked fluorescence, corrected for age, to the presence and
severity of diabetic microvascular complications. We found
significant associations between all four products and compli-
cation status. Because the levels of glycoxidation products,
rather than FL, seem to determine the altered properties of
collagen, our data suggest that "fixation" of initial glycative
damage by free radical oxidation reactions may be implicated
in the link between glycemic control and diabetic complica-
tions. Thus, in diabetic patients, individual variations in oxida-
tive stress may modulate the consequences of hyperglycemia,
and explain, in part, why the relationship between glycemic
control and complications is not a simple one.
Methods
Patients. 39 patients (27 male/ 12 female) were recruited from the
diabetes clinics ofthe Royal Victoria Hospital, Belfast, and Altnagelvin
Hospital, Londonderry, Northern Ireland. All had type I (insulin-de-
pendent) diabetes, diagnosed according to the criteria of the National
Diabetes Data Group (52). Their mean age was 41.5±15.3 (17-73) yr
(mean±l SD, range) and mean duration ofdiabetes 17.9±11.5 (0-46)
yr. Four patients had newly diagnosed diabetes. Each patient under-
went a full physical examination for the presence ofdiabetic complica-
tions, in addition to venous blood sampling and skin biopsy as outlined
below. Nondiabetic collagen was obtained from healthy donors or at
autopsy (donor age 47.6±25.9 [0.001-85] yr) at the Royal Victoria
Hospital, Belfast, as described (22).
Clinical examination. Retinal examination was performed by an
ophthalmologist. The fundi were graded by the absence or presence of
background or proliferative retinopathy. Blood pressure (average of
three readings) was recorded using a random zero sphygmomanometer
(Hawksley and Sons Ltd., Lancing, Sussex, UK) after 5 min ofrecum-
bency. Diastolic pressure was recorded at Korotkov phase V. The pres-
ence and degree of limitation of joint mobility (LJM) (53, 54) was
assessed by placing the hand palm down on a planar surface: normally
the whole palmar surface of the hand makes contact. Patients were
classified into those without LJM (stage 0), those unable to make con-
tact with any portion ofonly one finger, usually the proximal interpha-
langeal joint of the fifth (stage I), and those in whom two or more
fingers were involved, usually the fourth and fifth (stage II).
Quantitative measurements of the right brachial and right and left
posterior tibial pulses were made using a Doppler ultrasonic technique
(average ofthree readings). The right brachial and right ankle measure-
ments were expressed as a ratio (brachial/ankle systolic index). Assess-
ment of neurological function was made by estimation ofthe vibration
perception threshold using a biothesiometer (55) (Biomedical Instru-
ments, Newbury, OH) and expressed as the mean ofthree values from
each lateral malleolus and the distal end of each great toe.
Hemoglobin (Hb)AI was measured by agar gel electrophoresis as
previously described (26): the normal range in our laboratory is 3.6-
7.2%. For the entire patient group, HbA, was 11.4±2.4 (6.9-16.9)%
(mean±l SD, [range]). In 24 ofthe 39 patients, HbA1 had been mea-
sured every 3 mo since November 1982, and for each ofthese, a mean
HbAl (MHbA,) was calculated using all values obtained during the 6
yr preceding the study. For these 24 patients, MHbA, was 1.1±1. 7
(8.5-14.7)%, and correlated significantly with the most recent HbA,: r
= 0.78 (P < 0.0001 ).
Urine collection and analysis. A single 24-h urine collection was
performed at home by each patient for determination of albumin ex-
cretion rate (AER24) in micrograms per minute. In addition, an over-
night urine collection, performed within a few days of the 24-h collec-
tion, was available in 25 patients. While the categorization of patients
into normoalbuminuric (AER24 . 20 ,g/min), microalbuminuric (20
,gg/min < AER24 < 200 .Lg/min) and "macroalbuminuric" (AER24
2 200 ,g/min) groups was made using the 24-h urine sample, the
classification was confirmed by the overnight sample in all patients in
whom both urine collections were available. Any patient with a sus-
pected or proven urinary tract infection had urinary albumin estima-
tion deferred until urine culture was negative. Urinary albumin con-
centration was measured by 125I radioimmunoassay involving double
separation ofbound and free antigen (Diagnostic Products Ltd., Wal-
lingford, Oxfordshire, UK). The inter- and intraassay coefficients of
variation were 7% and 5%, respectively, detection limit 0.9 gg/ml.
Complication status. 14 patients had no retinopathy, 9 had back-
ground retinopathy, and 16 had proliferative retinopathy. Of 35 pa-
tients in whom AER24 was available, 26 had normoalbuminuria, 6 had
microalbuminuria, and 3 had macroalbuminuria. In the macroalbu-
minuric group, AER24 values were 525,694, and 1,071 gg/min. Analy-
sis ofdata involving AER24 was performed both including and exclud-
ing these macroalbuminuric values, for the statistical reasons detailed
below. Of38 patients examined for LJM, 18 had no LJM, 7 had stage I
LJM, and 13 stage II LJM.
Skin sampling and analysis. Details of skin biopsy technique are
provided in the accompanying paper (22). Measurements of collagen
FL, CML, pentosidine, and collagen-linked fluorescence are also de-
scribed briefly in the accompanying article (22), and in detail else-
where (23, 45-47). Laboratory analyses of the collagen samples were
performed without prior knowledge of sample identity. The correla-
tions between collagen FL and HbA, and between FL and MHbA1
were highly significant (r = 0.74 and r = 0.89, respectively (P
< 0.0001 )), confirming previous findings (24, 25). The study was ap-
proved by the Ethical Committees of the participating hospitals and by
the Human Subjects Review Board at the University of South Caro-
lina.
Statistical analysis. Data processing and statistical analyses were
performed using the Statistical Analysis System (SAS). Each of the
early and late products of glycation was examined according to the
presence and/or severity of a specific diabetic complication by a Krus-
kal-Wallis one-way analysis of variance. The relationships among
HbA,, MHbA1, and FL were examined using the Pearson correlation
coefficient, in that these variables were considered to be normally dis-
tributed. For analyses involving urinary albumin data (which was not
normally distributed), a Spearman correlation coefficient was used.
Analyses of data involving AER24 were performed both including and
excluding results for the three macroalbuminuric patients. This was
done in case bias should result from the high, "outlying," AER24 values
(> 2 SD from the mean for all patients) in these patients. Although the
inclusion of results for the macroalbuminuric patients tended to in-
crease the level of significance in some analyses, in general, the results
and conclusions were similar with or without these patients. Multiple
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Table I. Retinopathy Status and Levels ofMaillard Products in Skin Collagen
Background Proliferative
n No retinopathy n retinopathy n retinopathy P
Age (yr) 14 37.5±16.1 9 46.3±15.6 16 41.7±14.5 NS
(17-65) (29-73) (22-68)
Duration (yr) 14 $10.6±10.5 9 1123.5±10.4 16 **21.4±10.1 < 0.01
(0-38) (8-37) (10-46)
HbAI (%) 14 11.1±2.1 8 10.5±2.3 16 12.1±2.7 NS
(8.0-15.4) (6.9-14.2) (8.7-16.9)
MHbA1 (%) 4 10.3±2.0 7 10.7±1.3 13 11.6±1.7 NS
(8.5-13.1) (9.3-12.8) (9.1-14.7)
FILR 14 $2.79±1.02 8 3.32±0.41 15 **3.76±1.16 < 0.05
(1.84-5.09) (2.60-3.80) (2.32-5.87)
CMLR 14 §1.17±0.35 8 1"1.54±0.25 15 $*1.86±0.34 < 0.001
(0.60-1.76) (1.30-1.93) (1.33-2.37)
PentosidineR 12 * 1.25±0.60 6 1.73±0.51 11 '1.84±0.57 < 0.05
(0.52-2.47) (1.38-2.38) (1.07-2.83)
FluorescenceR 11 $1.17±0.26 6 1.36±0.27 10 **1.55±0.25 < 0.01
(0.84-1.65) (1.09-1.76) (1.20-1.91)
Data are given as means± I SD (range); NS, P > 0.05. P statistical analysis is performed using Kruskall-Wallis one-way analysis of variance.
Superscript "R" denotes age-corrected ratio. * P < 0.05 compared to any retinopathy; $ P < 0.01 compared to any retinopathy; I P < 0.001
compared to any retinopathy; 11 P < 0.05 compared to no retinopathy; 1 P < 0.05 compared to no retinopathy; ** P < 0.01 compared to no
retinopathy; $$ P < 0.001 compared to no retinopathy; " P < 0.05 compared to grade I retinopathy.
logistic regression analysis (56) was used to test several models of the
association ofa specific complication with the Maillard products, con-
trolling for age, sex, and duration ofdiabetes. For descriptive purposes
in tables and text, the arithmetic mean± 1 SD is quoted. The conven-
tional level of significance (P < 0.05) has been used in all analyses.
Measurements ofcollagen FL, CML, pentosidine, and fluorescence
were corrected for the recognized increase with age (22, 23) by express-
ing the observed value as a ratio of the predicted value for a control
patient ofthe same age (derived from the corresponding regression line
in the control population [22]). These calculated ratios are denoted by
the superscript "R" (e.g., CMLR). As the concentration of FL rises
rapidly in early life, but is only weakly related to age after age 20 yr, the
regression line for FL was estimated from the data for nondiabetic
control subjects between the ages of20 and 85 yr. In some cases( < 10%
of samples) insufficient collagen was available for all assays to be per-
formed. Consequently, there is some variation in the number of mea-
surements between analyses.
Results
The mean age, duration ofdiabetes, HbA,, MHbA,, and levels
of each of the Maillard products across the various grades of
retinopathy, nephropathy, and limited joint mobility are
shown in Tables I-III and Fig. 1-3.
Patients in the three retinopathy categories did not differ
significantly in age whether considered collectively (by analysis
of variance) or between subgroups (Table I). The severity of
retinopathy was related to the duration ofdiabetes (P < 0.01 ).
There was no association between HbA, or MHbA1 values and
retinopathy status. In contrast, age-corrected levels of skin col-
lagen FL, CML, pentosidine, and Maillard-type fluorescence
all increased progressively and significantly with the severity of
retinopathy (Table I, Fig. 1 ). These increases were most signifi-
cant for CML (P < 0.001 ) and for collagen-linked fluorescence
(P<0.0l).
Compared with normoalbuminuric patients, patients with
AER2' 2 20 ,og/min were ofslightly greater age and duration of
diabetes, and their HbAI, MHbA,, and collagen FL content
also tended to be higher: however, none of these differences
reached significance (Table II). In contrast, age-corrected lev-
els of skin collagen FL, CML, pentosidine, and fluorescence
were significantly higher in patients with AER24 2 20 ,gg/min
than in normoalbuminuric patients (Table II, Fig. 2). If data
for the three macroalbuminuric patients were excluded from
these analyses, age-corrected CML, pentosidine, and fluores-
cence remained significantly elevated in microalbuminuric
compared with normoalbuminuric patients (P < 0.05, P
< 0.05, P < 0.01, respectively), but the difference in FL levels
0
e
w!-
0
LU
w
1
W
FL CML PENTOSIDINE FLUORESCENCE
Figure 1. Maillard products in skin collagen and retinopathy status.
Grade 0, no retinopathy; grade 1, background retinopathy; grade 2,
proliferative retinopathy. Bars show mean± 1 SD in each category.
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Table II. AER2 and Levels ofMaillard Products in Skin Collagen
AER24 AER24
n < 20 g/min n . 20ug/min P
Age (yr) 27 41.9±14.6 9 44.6±16.9 NS
(17-68) (23-73)
Duration (yr) 27 17.2±12.2 6 22.9±9.0 NS
(0-46) (17-42)
HbA1 (%) 26 10.8±1.9 6 13.0±3.3 NS
(6.9-15.4) (8.7-16.9)
MHBAI (%) 17 10.8±1.5 7 11.8±1.9 NS
(8.5-13.3) (9.1-14.7)
FLR 25 3.00±0.92 9 3.99±1.28 < 0.05
(1.84-5.12) (2.32-5.87)
CMLR 25 1.37±0.36 9 1.99±0.31 < 0.001
(0.60-2.12) (1.43-2.37)
PentosidineR 21 1.41±0.56 6 2.29±0.32 < 0.01
(0.52-2.47) (2.05-2.83)
FluorescenceR 20 1.29±0.23 6 1.73±0.12 < 0.01
(0.96-1.76) (1.56-1.91)
Data are given as means±SD (range); NS, P > 0.05. P statistical
analysis is performed using Mann-Whitney U test. Superscript "R"
denotes age-corrected ratio.
was no longer statistically significant. When AER24 results
from all patients were analyzed together using the nonparamet-
ric Spearman correlation coefficient, there were significant
correlations between AER24 and MHbA,, FLR, CMLR, pento-
sidineR, and fluorescence R (Table IV). Exclusion of the three
macroalbuminuric patients from these analyses decreased the
correlations between AER24 and glycoxidation products
(CMLR, r = 0.33; pentosidineR, r = 0.38; fluorescence R, r
= 0.38 (all P = 0.06)), and MHbA,, and only the correlation
between AER24 and FLR remained significant (r = 0.44, P
< 0.05). If patients with micro- and macroalbuminuria were
considered together as a separate group (n = 9), none of the
glycation products correlated significantly with AER24.
Patients with LJM (Table III) had a longer duration of
diabetes than those without (P < 0.01) (also significant be-
tween grade 0 and grade 2 LJM, P < 0.01, and grade 1 and 2
LJM, P < 0.05). HbA1, MHbA,, and age-corrected collagen
FL values were similar between these categories. Age-corrected
CML, pentosidine, and Maillard-type fluorescence tended to
increase with more severeUM (Table III, Fig. 3) but this was
significant only for pentosidine and fluorescence, and only be-
tween patients with grade 0 and grade 2 disease (P < 0.05). In
these analyses (unlike the logistic regression models described
below), the Maillard products were not corrected for duration
of diabetes: the observation that age-adjusted pentosidine and
fluorescence showed the greatest correlations with duration of
diabetes (22) may be pertinent to these findings.
CML, pentosidine, and fluorescence correlated with sys-
tolic blood pressure, but no significant association was found
after the products were corrected for age. There was a signifi-
cant correlation between age-corrected CML and the brachial-
ankle systolic index (r = -0.51, P = 0.05), but this was not
observed with pentosidine or fluorescence. None of the prod-
ucts, after correction for age, correlated with measurements of
either ankle or toe vibration perception threshold.
The effect of each of the Maillard products on a specific
complication of diabetes was examined using logistic regres-
sion analysis. For each complication (defined as either present
or absent), serial models were examined containing a Maillard
product while simultaneously controlling for age, sex, and dura-
tion ofdiabetes (Tables V and VI). The unavailability ofsome
data points, particularly for pentosidine and fluorescence, de-
creased the power of their respective models. The addition of
Table III. LJM and Levels ofMaillard Reaction Products in Skin Collagen
LJM absent IJM present [JM present
n (gradeO) n (grade 1) n (grade 2) P
Age (yr) 18 38.7± 15.2 7 39.9± 15.9 13 45.3± 15.9 NS
(17-63) (22-65) (23-73)
Duration (yr) 18 *12.6±8.9 7 15.9±4.6 13 §'126.5±12.9 < 0.01
(0-27) (11-24) (0-46)
HbA1 17 11.5±2.0 7 11.5±2.8 13 11.5±3.0 NS
(8.0-16.9) (6.9-16.7) (6.9-16.7)
MHbAj(%) 11 11.4±2.0 5 11.7±1.4 7 10.5±0.9 NS
(8.5-14.7) (10.2-13.3) (9.1-11.6)
FLR 17 3.43±1.21 6 3.46±0.92 13 3.09±0.98 NS
(1.92-5.82) (2.22-4.54) (1.84-5.87)
CMLR 17 1.41±0.45 6 1.63±0.60 13 1.66±0.36 NS
(0.60-2.35) (0.91-2.37) (1.02-2.31)
PentosidineR 13 1.36±0.56 5 1.44±0.62 10 *1.96±0.59 NS
(0.52-2.17) (0.95-2.51) (1.11-2.83)
FluorescenceR 13 1.27±0.30 4 1.29±0.37 9 t1.52±0.24 NS
(0.84-1.90) (1.02-1.82) (1.07-1.76)
Data are given as means±SD (range); NS, P > 0.05. P statistical analysis is performed using the Mann-Whitney U test. Superscript "R" denotes
age-corrected ratio. * P < 0.05 compared to the presence of LJM; $ P < 0.05 grade 2 LJM compared to grade 0 LJM; § P < 0.01 grade 2
LJM compared to grade 0 [JM; "lP < 0.05 grade 1 LJM compared to grade 2 LJM.
Maillard Reaction Products and Diabetic Complications 2473
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Figure 2. Maillard products in skin collagen and albumin excretion
rate. N, normoalbuminuria (AER24 < 20 ttg/min); A, nephropathy
(as defined in text) (AER24 2 20 Ag/min). Bars show mean±l SD
in each category.
either HbA1 or MHbA1 made no further contribution to any
model, and so neither was included in the analyses.
Skin collagen FL and CML were significant independent
variables associated with the presence of retinopathy (Table
V). A 20% increment in FL or CML was associated with an
increased odds ofretinopathy (FL odds ratio (OR) = 1.06, 95%
confidence interval (CI) 1.01-1.12, P < 0.05; CMLOR = 6.77;
95% CI 1.33-34.56, P < 0.05). In smaller models, similarly
controlling for age, sex, and duration of diabetes, neither pen-
tosidine nor fluorescence was associated with retinopathy, al-
though fluorescence approached significance: for a 20% incre-
ment in fluorescence the OR was 2.37 (95%CI 0.98-5.20), P
= 0.05.
Skin collagen FL and CML were also significant indepen-
dent variables associated with the presence of early nephropa-
thy (AER24 2 20 ,g/min) (Table VI). A 20% increment in FL
or CML was associated with an increased odds of early ne-
phropathy (FL OR = 1.05, 95%CI 1.0 1-1.10, P < 0.05; CML
OR = 13.44, 95%CI 2.00-93.30, P < 0.01). Pentosidine ap-
proached significance as an independent variable associated
with early nephropathy (OR = 1.11, 95% CI 1.00-1.23, P
= 0.05). Ifthe three macroalbuminuric patients were excluded
from the analyses, only CML emerged as a significant indepen-
dent variable associated with microalbuminuria (OR = 9.70,
Table IV. AER24: Correlations with Levels ofMaillard Products
in Skin Collagen
r* P n
HbAI (%) 0.33 0.055 35
MHbA, (%) 0.49 0.016 24
FLR 0.52 0.002 34
CMLR 0.44 0.009 34
PentosidineR 0.44 0.022 27
FluorescenceR 0.47 0.016 26
Superscript "R" denotes age-corrected ratio. * Spearman correlation
coefficients.
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Figure 3. Maillard products in skin collagen and grade of LJM.
Grades ofLJM are defined in the text. Bars show mean± 1 SD in each
category.
95%CI 1.48-63.53, P < 0.01), with pentosidine again ap-
proaching significance (OR = 1.12, 95%CI 0.99-1.26, P
= 0.07). None of the Maillard products was independently
associated with limited joint mobility.
Table V. Retinopathy Status and Levels ofMaillard Products
in Skin Collagen, Controlledfor Age, Sex, and Duration
ofDiabetes: Multiple Logistic Regression Models
Dependent variable: Retinopathy (present/absent)
Parameter
Variable estimate SE P2p
Intercept -3.40 1.91 3.18 0.07
Age (yr) -0.07 0.05 2.45 0.12
Sex -1.79 1.14 2.47 0.12
Duration (yr) 0.20 0.07 7.38 0.01
FL* 0.30 0.13 4.92 0.03
Intercept -0.04 1.44 0.01 0.98
Age (yr) -0.26 0.11 5.54 0.02
Sex -2.04 1.35 2.31 0.12
Duration (yr) 0.12 0.07 3.18 0.07
CML* 9.57 4.16 5.29 0.02
Intercept 0.42 1.46 0.09 0.77
Age (yr) -0.08 0.07 1.50 0.22
Sex -1.43 0.97 2.18 0.14
Duration (yr) 0.13 0.07 3.52 0.06
Pentosidinet 0.06 0.08 0.69 0.41
Intercept 0.39 1.44 0.07 0.79
Age (yr) -0.21 0.10 4.40 0.04
Sex -2.62 1.39 3.58 0.06
Duration (yr) 0.11 0.07 2.81 0.09
Fluorescence* 4.10 2.11 3.77 0.05
* Two observations were missing from the model containing FL and
CML. * Seven observations were missing from each of the models
containing pentosidine and fluorescence.
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Table VI. AER24 and Levels ofMaillard Products
in Skin Collagen, Controlledfor Age, Sex, and Duration
ofDiabetes: Multiple Logistic Regression Models
Dependent variable: AER24> jig/min (present/absent)
Parameter
Variable estimate SE x2 P
Intercept -5.42 2.34 5.37 0.02
Age (yr) -0.02 0.04 0.40 0.53
Sex 0.06 1.00 0.01 0.95
Duration (yr) 0.07 0.06 1.59 0.21
FL* 0.25 0.11 4.77 0.03
Intercept -4.53 2.55 3.15 0.08
Age (yr) -0.27 0.10 6.76 0.01
Sex 1.72 1.32 1.70 0.19
Duration (yr) -0.10 0.08 1.46 0.23
CML* 13.15 4.87 7.28 0.007
Intercept 4.18 3.46 1.46 0.23
Age (yr) -0.44 0.24 3.48 0.06
Sex 1.15 1.35 0.72 0.40
Duration (yr) -0.24 0.16 2.28 0.13
Pentosidinet 0.52 0.27 3.82 0.05
* Five observations were missing from each of the models containing
FL and CML. t 10 observations were missing from each of the
models containing pentosidine and fluorescence. Convergence was
not obtained with the model containing fluorescence after 1,000
iterations.
Discussion
Several studies have reported a link between Maillard reaction
products in collagen and the complications of diabetes (32,
41-44, 49). In some, levels ofdiscrete products (32, 42, 43, 49)
were related to a single complication (42, 43, 49); in others, the
conclusions were inferred from analyses of measurements of
collagen-linked fluorescence (41, 44). It is now recognized that
nonglycation products, such as those derived from lipid peroxi-
dation, have similar fluorescence spectra to carbohydrate-de-
rived Maillard products. Because these nonglycation com-
pounds may become covalently bound to collagen, they may
contribute to total collagen fluorescence (44, 57, 58). A
strength ofthe present study is the focus on structurally charac-
terized products ofthe Maillard reaction which have been iden-
tified in glycated proteins both in vitro and in vivo.
As summarized in Figs. 1-3, both early (FL) and late
(CML, pentosidine, and fluorescence) Maillard products in
skin collagen increased with the presence and severity of dia-
'betic retinopathy. In each case there was a significant increase
between patients with grade 0 and grade 2 retinopathy, and for
CML between grade 0 and grade 1, and between grade 1 and
grade 2, disease. These and other data discussed below are con-
sistent with a pathophysiological role for glycation and glycoxi-
dation of proteins in diabetic retinopathy, and suggest that the
extent of modification of collagen in skin may be indicative of
the level of damage in other tissues, including perhaps, retinal
capillary basement membrane proteins. In accordance with
our findings, an increase in age-adjusted skin collagen pentosi-
dine levels with increasing severity of retinopathy was recently
reported by Sell et al. (32). The relevance of age and duration
of diabetes both to the development of complications and to
the levels of glycoxidation products in skin collagen is evident
in the present study and the preceding article (22). Controlling
for these variables, both skin collagen FL and CML content
remained independently associated with retinopathy, and the
association offluorescence with retinopathy approached signifi-
cance (P = 0.05) (Table V). Unavailable patient data and the
stronger correlation of pentosidine than the other products
with duration of diabetes (22) may have contributed to the
failure of pentosidine to predict retinopathy, even though it
increased significantly across the various grades ofretinopathy.
It was somewhat surprising that HbA, and mean HbAI, in
contrast to collagen FL, were not associated with retinopathy,
particularly in light of previous findings ( 12). Monnier et al.
(41 ) also failed to find a correlation between HbA, and retinop-
athy. The discrepancy between this and the previous study ( 12)
may reflect a smaller variation in glycemia, differing patient
characteristics, and a smaller patient cohort than reported pre-
viously.
Another new, and potentially important finding is the in-
crease in concentrations of age-corrected FL, CML, pentosi-
dine, and Maillard-type fluorescence in skin collagen from pa-
tients with early nephropathy compared with those who had
normal albumin excretion. For the glycoxidation products and
fluorescence, these increases remained significant when the mi-
croalbuminuric patients alone were compared with those who
had normal albumin excretion. Using a less stringent definition
of nephropathy (daily protein excretion > 0.5 g), Monnier,
Sell, and co-workers have previously described trends towards
increased skin collagen pentosidine (32) and fluorescence (41 )
in nephropathic compared to nonnephropathic diabetic pa-
tients, but the differences were not statistically significant. In
the present study, both early and late glycation products, and
MHbA1, correlated with AER24 in the entire patient group
(Table IV). The lack ofcorrelation between these products and
AER24 in the nine patients whose AER24 exceeded 20 Ag/min
is of uncertain significance, inasmuch as there is little power to
show an effect in such a small number of patients. Controlling
for age and duration ofdiabetes using logistic regression analy-
ses, FL and CML were independently associated with the pres-
ence of nephropathy, and pentosidine approached significance
(P = 0.05) (Table VI). These findings suggest that if the accu-
mulation ofglycation and glycoxidation products in skin colla-
gen is reflected in renal tissue proteins, then these modifica-
tions may be relevant to the earliest stages ofdiabetic nephropa-
thy. Putatively, modification of glomerular basement
membranes could contribute to altered permeability, initially
through charge-dependent mechanisms such as a decrease in
anionic proteoglycans and immobilization ofplasma proteins,
later progressing to permanent structural damage and alter-
ation of pore size (40). Also, the ability of advanced Maillard
products to quench the vasodilator (59) and antiproliferative
(60) effects of nitric oxide has recently been recognized, and
may be implicated in the pathogenesis of diabetic nephro-
pathy (60).
Two recent studies have estimated Maillard products in
both diabetic and control subjects with varying degrees ofrenal
impairment. In one (49), pentosidine was measured in skin
collagen, while in the other (43) a new whole-cell macrophage
ligand-binding assay was used to provide a quantitative esti-
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mate of the concentration of Maillard products in both serum
and arterial tissue proteins. Both studies demonstrated signifi-
cant accumulation of these products in patients with end-stage
renal failure, whether or not diabetes was present. Sell and
Monnier (49) found no increase in pentosidine in skin collagen
from nonnephropathic type 2 (non-insulin-dependent) dia-
betic patients compared with nondiabetic control subjects.
However, in a more recent study (32), they reported increased
pentosidine levels (more than twofold) in nonnephropathic
type 1 (insulin-dependent) diabetic patients compared with
control subjects. Our findings, in agreement with the latter
study, suggest that the increase in pentosidine (and other Mail-
lard products) is a characteristic of the diabetic population in
general, and is not confined to patients with renal disease.
The significance of limitation of joint mobility in diabetes
remains unclear. In the present study, there was a tendency for
the Maillard products to increase with the severity of LJM, but
the increase was significant only for age-corrected pentosidine
and fluorescence and only between grades 0 and 2 LJM. Sell,
Monnier, and co-workers also found significant associations
between both pentosidine (32) and fluorescence (41) and the
presence of LJM. However, in our study, by using logistic re-
gression analysis to control for duration of diabetes, no signifi-
cant associations between Maillard products and LJM re-
mained, and in previous (unpublished) findings, we were un-
able to find a correlation between LJM and long-term glycemic
control (serial HbA, measurements over a 6-yr period). In the
present study, neurologic function, as evidenced by measure-
ments of ankle and toe vibration perception threshold, was
unrelated to levels of Maillard products in skin collagen. This is
consistent with the thesis that other processes, such as osmotic
effects from increased sorbitol pathway activity, may be of
greater relevance than protein glycoxidation to the develop-
ment of diabetic neuropathy.
Although correlations were found between levels of Mail-
lard products and arterial blood pressure, these did not persist
after correction for age. Unlike Monnier et al. (41 ), we found
no association of blood pressure with severity of retinopathy,
nor with the presence of early nephropathy. Age-corrected
CML was weakly associated with the brachial-ankle systolic
index. A related finding by Monnier et al. (41), correlating
collagen-linked fluorescence and arterial stiffness, supports the
conclusion that widespread collagen browning may be impli-
cated in the development of diabetic macrovascular disease.
It is acknowledged that with the small number ofpatients in
the present study, the results of logistic regression analysis must
be interpreted with caution. However, when considered to-
gether with the significant mean differences across the various
complication subgroups, the findings are consistent with a role
for glycation and glycoxidation of proteins in the development
of the microvascular complications of diabetes. The indepen-
dent association of skin collagen FL with diabetic retinopathy
and early nephropathy may imply a direct pathogenic role for
glycated structural proteins in the affected tissues. However,
any explanation must take into account the fact that FL levels
in collagen rise rapidly after the onset of diabetes and that the
increase is reversible with short-term improvements in glyce-
mic control (26). In contrast, complications develop only
slowly over a period of years. Alternative explanations for the
association between increased collagen FL and the develop-
ment of complications include the possibility that chronic hy-
perglycemia leads to both consequences through entirely sepa-
rate mechanisms, or, as we suggest, that the link may be indi-
rect, inasmuch as in addition to glycation, oxidation is
necessary to produce permanent alterations to proteins (37).
The latter hypothesis is supported by studies using aminoguani-
dine, which does not influence FL formation, but which in-
hibits collagen cross-linking in vivo (61 ) and the formation of
CML and pentosidine in vitro (Fu et al., manuscript in prepara-
tion). In animal models, aminoguanidine has been shown to
retard the development ofdiabetic retinopathy (62), nephropa-
thy (63), and neuropathy (64).
As with collagen FL, the finding of increased concentra-
tions of glycoxidation products in association with diabetic
complications does not prove a causal relationship. Glycoxida-
tion may be only one of perhaps several, possibly interrelated
mechanisms (65) altering the properties not just of collagen,
but also of other extracellular matrix constituents: abnormali-
ties ofprotein synthesis, hydroxylation and turnover have been
described (66-68). The pathophysiological relevance of gly-
coxidation products in diabetes is also controversial on quanti-
tative grounds. CML and pentosidine are present in little more
than trace amounts in collagen. Despite this, they may be re-
garded as biomarkers of total glycoxidative damage (6), most
ofwhich results in the formation ofother products whose chem-
ical structures are, as of now, uncharacterized.
If the accumulation of glycoxidation products does indeed
contribute to the development of diabetic complications, then
the ability ofan individual to resist oxidative stress may modu-
late the consequences of hyperglycemia. Prospective studies
are needed to determine whether those diabetic patients who
accumulate glycoxidation products unusually rapidly (control-
ling for long-term glycemia), i.e., subjects with the weakest
antioxidant defense mechanisms, represent a subgroup which
is particularly vulnerable to the development ofcomplications.
In the future, inhibition not only of glycation (by improved
glycemic control), but also of oxidative stress (by dietary and
pharmacologic manipulations), may offer a logical approach
to the prevention of diabetic complications.
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